Day: November 22, 2024
Precision BioSciences to Participate in Upcoming November Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
– PBGENE-HBV preclinical data reinforce safety profile and potential to deliver a functional cure for chronic hepatitis B, supporting advancement into first-in-human clinical study – – Phase 1 dose escalation and expansion trial, ELIMINATE-B, designed to assess safety and efficacy measured by
Precision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
- Received approval for first Clinical Trial Application to advance PBGENE-HBV into first-in-human trials for treatment of chronic hepatitis B; additional global regulatory applications pending approval - Opened PBGENE-HBV phase 1 clinical program in Moldova ; patient screening underway with
Precision BioSciences to Report Third Quarter Results on November 4, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 28, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced it will host a Hepatitis B
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
- Stimulating gene editing by homology-directed repair (HDR) has the potential advantage of being able to achieve any type of edit, including gene insertion - ARCUS approach potentially offers broader therapeutic than current gene editing modalities for diseases that require a gain in function
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
- Clinical Trial Application accepted in Moldova with additional regulatory applications pending approval - PBGENE-HBV is the first in vivo gene editing program for chronic hepatitis B virus to move into global clinical trials - Company to host investor event highlighting clinical candidate safety
Precision BioSciences to Participate in Upcoming Longwood Boston CEO and Guggenheim Healthcare Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the
Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Congress
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 16, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL) is an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion which is necessary for